scholarly journals Scleral Buckling Surgery For Stage 4A and 4B Retinopathy of Prematurity in Critically Ill Neonates.

2021 ◽  
Author(s):  
Eleni Papageorgiou ◽  
Konstantina Riri ◽  
Dimitrios Kardaras ◽  
Ioanna Grivea ◽  
Asimina Mataftsi ◽  
...  
Keyword(s):  
Critically Ill ◽  
Retinopathy Of Prematurity ◽  
Scleral Buckling ◽  
Intravitreal Ranibizumab ◽  
Stage 4 ◽  
Age At Surgery ◽  
Vitreoretinal Traction ◽  
Visual Potential ◽  
Critically Ill Neonates

Abstract Purpose: To determine the efficacy of scleral buckling in eyes with stage 4A and 4B retinopathy of prematurity (ROP).Methods: Seven eyes of five premature infants underwent scleral buckling for stage 4 ROP in zone II. Five eyes had stage 4A ROP, and two eyes had stage 4B ROP. Six eyes had previous diode laser photocoagulation, and one eye had received an intravitreal ranibizumab injection. Scleral buckling was the procedure of choice due to lack of access to specialized pediatric vitrectomy instrumentation. Average age at surgery was 3.4 months. Postoperative anatomic retinal status, visual acuity outcome and refractive error were assessed. Results: The scleral buckle was removed on average 8 months after surgery. Retinal reattachment was achieved in all seven eyes. At final follow-up one eye had macular ectopia and disc dragging, one eye had a macular traction fold and two eyes had optic disc pallor. Average myopic error after buckle removal was -7.5 D.Conclusion: Scleral buckling can be performed safely and effectively in 4A and 4B stage ROP in critically-ill infants, when access to specialized pediatric vitrectomy instrumentation is limited. This surgical technique may provide adequate relief of vitreoretinal traction with improved visual potential.

scholarly journals Scleral buckling surgery for stage 4A and 4B retinopathy of prematurity in critically ill neonates

2021 ◽  
Author(s):  
Eleni Papageorgiou ◽  
Konstantina Riri ◽  
Dimitrios Kardaras ◽  
Ioanna Grivea ◽  
Asimina Mataftsi ◽  
...  
Keyword(s):  
Critically Ill ◽  
Retinopathy Of Prematurity ◽  
Scleral Buckling ◽  
Critically Ill Neonates

Presumptive Neonatal Multisystem Inflammatory Syndrome in Children Associated with Coronavirus Disease 2019

2021 ◽  
Author(s):  
Abhay A. Divekar ◽  
Pisespong Patamasucon ◽  
Joshua S. Benjamin
Keyword(s):  
Coronary Artery ◽  
Ventricular Function ◽  
Critically Ill ◽  
High Index ◽  
Standard Medical Therapy ◽  
Key Points ◽  
Critically Ill Neonates ◽  
High Index Of Suspicion ◽  
Inflammatory Syndrome

Objective The study aimed to alert the neonatal community to the possibility of multisystem inflammatory syndrome in children (MIS-C) like disease in critically ill neonates born to mothers with coronavirus disease 2019 (COVID-19). Study Design Diagnosis of MIS-C like disease was pursued after echocardiography showed severely depressed ventricular function and pathological coronary artery dilation in the setting of medically refractory multisystem organ failure and maternal COVID-19 infection. The neonate did not respond to standard medical therapy, and there was no alternative disease that could explain the clinical course. High index of clinical suspicion coupled with low risk of intravenous immunoglobulin (IVIG) prompted us to pursue IVIG administration even though the neonate did not meet classic criteria for MIS-C. Result Following treatment with IVIG, there was rapid clinical improvement. Ventricular function improved within 15 hours and coronary artery dilation resolved in 8 days. There was no recurrence of disease during follow-up. Conclusion COVID-19 associated MIS-C like disease has not been well described in neonates. As typical features may be conspicuously absent, a high index of suspicion is warranted in critically ill neonates born to mothers with COVID-19. Echocardiography may provide critical diagnostic information and narrow the differential diagnosis. Key Points

Scleral buckling surgery in stage 4 retinopathy of prematurity

1996 ◽  
Vol 234 (S1) ◽  
pp. S38-S41 ◽  
Author(s):  
Benedetto Ricci ◽  
Alessandro Santo ◽  
Francesco Ricci ◽  
Giuseppe Minicucci ◽  
Fernando Molle
Keyword(s):  
Retinopathy Of Prematurity ◽  
Scleral Buckling ◽  
Stage 4

INTRAVITREAL RANIBIZUMAB INJECTION AS TREATMENT IN PATIENTS WITH TYPE 1 RETINOPATHY OF PREMATURITY

2021 ◽  
pp. 13-15
Author(s):  
Kalishankar Das ◽  
Athokpam Poireiton ◽  
Sneha Bhowmick
Keyword(s):  
Cohort Study ◽  
Intravitreal Injection ◽  
Retinopathy Of Prematurity ◽  
Positive Response ◽  
Primary Treatment ◽  
Intravitreal Ranibizumab ◽  
Response Group ◽  
Type 1 Rop

Aim: To investigate the anatomic outcomes of patients treated with intravitreal ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP). A prospective cohort study was done including 100 eyes of Material And Method: 60 patients with type 1 ROP treated with intravitreal injection of ranibizumab (IVR) (0.25 mg/ 0.025 ml) as primary treatment from June 2018 to November 2019 over a period of 18 months. The anatomic outcomes were analyzed and follow-up were done upto 6 months. There were a Result: total of 94 eyes (94.0%) in the positive response group and 6 eyes (6.0%) in the negative/no response group after IVR. Within the positive response group, 49 eyes (52.13%) were in the regression without laser subgroup, and 45 eyes (47.87%) were in the regression with laser subgroup. Conclusion: Intravitreal injection of ranibizumab seemed to be effective in treating patients with type 1 ROP.

scholarly journals Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage

2016 ◽  
Vol 2016 ◽  
pp. 1-6
Author(s):  
Yu Xu ◽  
Xiaoli Kang ◽  
Qi Zhang ◽  
Qiujing Huang ◽  
Jiao Lv ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Vitreous Hemorrhage ◽  
Primary Treatment ◽  
Intravitreal Ranibizumab ◽  
Case Series Study ◽  
The Mean ◽  
Mean Time

To investigate the efficacy of intravitreal ranibizumab (IVR) combined with laser photocoagulation for aggressive posterior retinopathy of prematurity (AP-ROP) patients with vitreous hemorrhage, we conducted a retrospective observational case series study. A total of 37 eyes of 20 patients’ medical records were reviewed. Patients first received IVR (0.25 mg/0.025 mL) and later photocoagulation. The mean postconceptual age of injection was 34.6 ± 1.4 weeks, and the mean follow-up period was 39.3 ± 8.3 weeks. During the follow-up, 96.6% eyes had various degree of rapid absorption of vitreous hemorrhage after IVR. The mean time of received first photocoagulation after IVR was 4.8 ± 2.9 weeks. Ten (27.0%) eyes received second laser therapy and the mean time of second laser therapy after IVR was 3.2 ± 0.8 weeks. All eyes exhibited adequate regression of ROP and were stable with attached retina. Fibrosis membrane was observed in seven eyes (18.9%) and three of them demonstrated mild ectopic macula. No significant side effects related to IVR were observed. So IVR could be conducted as primary treatment of AP-ROP associated with vitreous hemorrhage, which can improve the fundus visibility, followed by conventional photocoagulation. Further randomized controlled trials are necessary to compare the clinical efficacy and safety with conventional interventions.

Sign in / Sign up

Export Citation Format

Share Document